TME Pharma NV is a clinical-stage biopharmaceutical company, which focuses on therapeutics targeting the tumor microenvironment or TME. The firm is active in pioneering the development of a new class of proprietary therapeutics called Spiegelmers. Its pipeline includes NOX-A12 and NOX-E36. The company was founded on January 16, 2015 and is headquartered in Berlin, Germany.